Home Blog

VIVO Cannabis Announces Results of 2022 AGM and Election of New Directors

0

Toronto, Ontario–(Newsfile Corp. – July 2, 2022) – VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) ("VIVO" or the "Company"), a leading provider of premium cannabis products and services, is pleased to announce the results of its annual general and special meeting of shareholders held today (the "Meeting").

As announced this morning, at the Meeting, shareholders approved fixing the number of directors at five, and the election of Ray Laflamme, Glen Huber, Shai Altman, Eric Shipman and Holly Workman as directors of the Company.

Mr. Laflamme is a founder and the current President of Canna Farms Limited, a wholly owned subsidiary of the Company, and all of the directors are previous directors of VIVO.

"I am pleased with the outcome of today’s AGM," said Ray Laflamme, VIVO’s CEO and Chair of the Board. "VIVO’s domestic and international businesses continue to perform well despite significant industry headwinds, and it is reassuring to have the support of a strong board and dedicated hard-working teams as we work towards leveraging VIVO’s solid position in the Canadian and in the global medical cannabis markets. We will continue to build on our core assets: a dedicated medical focus, excellent customer service, fair pricing, and top quality products and services."

The Company also announces that the board has appointed the following officers of the Company:

Name    Office Held
Ray Laflamme Chief Executive Officer
Michael Bumby Chief Financial Officer
Carole Chan Chief Commercial and People Officer, and President, Harvest Medicine
Mariana Fonar General Counsel and Corporate Secretary
Andreas Sander President, European Operations

 

All of the officers are previous officers of VIVO.

A total of 88,982,498 common shares were voted at the Meeting, representing 23.991% of the votes attached to all outstanding common shares of the Company. The election of directors was voted upon by ballot and the detailed voting results on that matter are set out below:

Director Number of Votes
FOR
Number of Votes
Withheld
Percentage of Votes Cast FOR Matter
Ray Laflamme 64,815,915 4,528,551 93.47%
Glen Huber 64,992,148 4,352,318 93.72%
Shai Altman 64,828,183 4,516,283 93.49%
Eric Shipman 63,980,174 5,364,292 92.26%
Holly Workman 63,881,003 5,463,463 92.12%

 

In addition, the Company’s shareholders approved the appointment of MNP LLP as auditor of the Company for the 2022 fiscal year. Detailed voting results for the Meeting will be included in the Report on Voting Results to be filed under the Company’s profile on SEDAR at www.sedar.com.

About VIVO Cannabis

VIVO Cannabis is recognized for trusted, premium cannabis products and services. Through its Canna Farms and ABcann business units, VIVO holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms, Beacon Medical, Fireside, and Lumina. Harvest Medicine, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 200,000 patient visits. VIVO is always pursuing partnership and product development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com

For further information:

VIVO Investor Relations
Michael Bumby, Chief Financial Officer
[email protected]

Instagram: https://www.instagram.com/vivo_cannabis/
Facebook: https://www.facebook.com/vivocanna/
Twitter: https://twitter.com/vivo_cannabis
LinkedIn: https://www.linkedin.com/company/vivo-cannabis-inc/

Disclaimer for Forward-Looking Information

Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Forward-looking statements in this news release include statements regarding the Company’s intent to identify an additional independent director, and plans to work towards lower costs, increased revenue and profitability. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward‐looking statements, including: that the Company may not be able to achieve competitive margins; that new products, if launched, may not be accepted by the market or may become subject to product liability claims; that the Company may not be able to obtain necessary licences; that demand for the Company’s products may not meet management’s expectations; that the COVID‐19 pandemic may last longer and have a more significant impact on the Company’s operations, the Canadian cannabis industry, or the global economy generally, than currently expected; that the Company faces competition from existing and new market entrants and participants; that the Company may be unable to retain its key talent or attract new talent and/or potential independent directors; that the Company may not be able to execute on its strategic partnerships; that the Company may not obtain any other necessary regulatory approvals as required from time to time; that the Company may be unable to protect its intellectual property; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward‐looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully, and the more extensive risk factors included in the Company’s management’s discussion and analysis for the three months ended March 31, 2022, which is available on SEDAR, in evaluating the forward‐looking statements contained in this news release and are cautioned not to place undue reliance on such forward‐looking statements, which are qualified in their entirety by these cautionary statements. The forward‐looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward‐looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129837

Aion Therapeutic Announces Intellectual Property Sale and Management and Board Changes

0

Toronto, Ontario–(Newsfile Corp. – June 30, 2022) – Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company“) announced today that it has sold four patent applications and all associated supporting data to Apollon Formularies PLC (“Apollon“), a UK based international pharmaceutical company listed for trading on the Aquis Stock Exchange. Furthermore, Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic.

Under the terms of an asset purchase agreement (the “APA“), the Company has sold four patent applications, and all associated supporting data to Apollon (collectively, the “Intellectual Property“) as detailed below:

  • Compositions and Methods for Treatment of Cancers;
  • Compositions and Methods for Treatment of Inflammation;
  • Methods for Treatment of Human Cancers Using Mushroom Compositions; and
  • Methods for Treatment of Human Cancers Using Cannabis Compositions.

In consideration for the Intellectual Property, Apollon has (i) issued to Aion Therapeutic an aggregate of 4,348,679 common shares of Apollon at a deemed price of £0.066 per share; and (ii) agreed to pay to Aion Therapeutic an indefinite royalty fee of 4% of the global net revenue generated by the Intellectual Property (the “Royalty“). The Royalty is payable quarterly in arrears, commencing upon the first commercial product sales utilizing the Intellectual Property.

The Company has retained the following patent applications:

  • Compositions and Methods for Treatment of Psychoses and Psychotic Disorders;
  • Compositions and Methods for Promoting Weight Loss and for Treatment of Obesity;
  • Antiviral Compositions and Methods for Their Use;
  • Compositions For Treatment of Interstitial Cystitis and Other Bladder Disease;
  • Cannabis Compositions and Emulsions; and
  • Cannabis Compositions and Nanoemulsions.

Graham Simmonds, Chief Executive Officer of Aion Therapeutic, stated, “The Company has sold its intellectual property to Apollon associated with the treatment of cancer and inflammation which will allow Aion Therapeutic to focus on product development and intellectual property development related to a range of innovative plant-based wellness products including cannabinoids and functional mushrooms in Jamaica and North America. Aion Therapeutic also continues to be a long-term believer in the potential of psilocybin mushrooms and other psychedelic ingredients in the areas of mental health and wellness treatments and will leverage the regulatory landscape and its presence in Jamaica to drive forward operation of Aion International Center for Psychedelic Psychiatry.”

This repositioning of the Company’s assets will provide for a more streamlined approach to the commercialization of functional wellness-based products and treatments while still having shareholders benefiting through Royalties and stock ownership from Apollon’s focus on the treatment of cancer and inflammation.

The APA was unanimously approved by all disinterested directors of the Company. Dr. Barnhill is the Chairman and Chief Executive Officer of Apollon and abstained from voting to approve the APA.

Furthermore, the Company announced that Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and from all subsidiary level appointments, and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic, with both resignations effective June 30, 2022. The Company would like to thank Dr. Barnhill and Dr. Fritsche for their respective contributions and wish them success in their future endeavors.

In connection with Dr. Barnhill’s resignation, Aion Therapeutic has issued an aggregate of 5,500,000 common shares of the Company at a deemed price of $0.05 per share to settle all amounts owing by Aion Therapeutic and its subsidiaries to Dr. Barnhill (the “Settlement Transaction“). The common shares issued to Dr. Barnhill are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation, and such further restrictions as apply under foreign securities laws.

The Settlement Transaction constituted a “related party transaction” as defined in Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions (“MI 61-101“), as Dr. Barnhill was a director of Aion Therapeutic at the time of the Settlement Transaction and acquired an aggregate of 5,500,000 common shares of the Company. The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a), respectively, of MI 61-101, as the fair market value of the common shares issued to Dr. Barnhill does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party transaction at least 21 days before the closing of the transaction, which the Company deems reasonable in order to complete the Settlement Transaction in an expeditious manner. The Settlement Transaction was unanimously approved by all disinterested directors of the Company.

About Aion Therapeutic Inc.

Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.

For further information, please contact:

Aion Therapeutic Inc.
Graham Simmonds
Executive Vice Chair & CEO
(416) 843-2881

DISCLAIMER & READER ADVISORY

Certain information set forth in this news release may contain forward-looking information that involve substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129672

BioHarvest Sciences Inc. Announces Appointment of Gavriel Lambert to the Board of Advisors

0

  • Gavriel Lambert’s 27 years of investment banking experience, covering the consumer and retail sectors and working on numerous capital markets transactions including IPOs, financings and M&A, will significantly enhance the Board of Advisors.
  • His appointment continues to demonstrate the Company’s resolve to partner with top life science and Cannabis companies.

Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – June 30, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) today announced that effective immediately, Gavriel Lambert will be serving on its Board of Advisors. Gavriel brings 27 years of experience in global investment banking and will complement BioHarvest’s highly competent Board of Advisors.

Ilan Sobel, CEO of BioHarvest, said: “Gavriel’s extensive experience in banking comes at an important junction of the company’s evolution as it seeks new partnerships with several US and international entities that would accelerate the market reach of BHSC’s products and technology. Not only will he help introduce us to the right strategic partners but he will also assist us in the process of achieving the best possible agreements. Furthermore, his capital markets experience will offer us valuable advice as a public company.

Gavriel Lambert said: “I strongly believe in the power of the Bio-Plant CELLicitation™ technology that BioHarvest brought to the world. This proprietary technology is set to make a significant impact in the life science-based businesses and as such is attractive to a large array of US and international companies covering multiple multi billion dollars’ verticals including Cannabis, Food, Nutraceuticals, Biotech and Pharma. The Cannabis vertical in particular is very promising given the fundamental difference BioHarvest can make in this industry. I look forward to working with my fellow advisors and senior management.

Detailed Biography

As of May 22, Gavriel has been appointed Head of Consumer Retail Group, EMEA (Europe, Middle East and Africa) and Co-Head of Global Retail for Jefferies Group.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2022/06/bioharvest-sciences-inc-announces-appointment-of-gavriel-lambert-to-the-board-of-advisors.jpg?w=696&ssl=1

Gavriel Lambert BioHarvest Sciences Board of Advisors

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/129651_aba01b0a54f34b31_001full.jpg

Prior to this new appointment and from 2016, Gavriel headed the EMEA Consumer Retail Group for Barclays Plc. He led a team of global professionals with primary coverage responsibility, client development, new business solicitation, transaction origination and execution for a broad range of retail, consumer and e-commerce clients. He has been involved in several dozens of significant M&A and financing transactions.

Prior to joining Barclays in 2013, his extensive career (that started in 1995) included holding senior investment banking positions at Solomon Smith Barney, J.P. Morgan and UBS Securities.

Gavriel holds a Master’s degree (MBA) in finance from the Columbia Business School and a BSc Honors in Psychology from the London School of Economics.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit:www.bioharvest.com.

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: [email protected]

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company’s products for new forms of medical treatments. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis, whether in North America or other global markets. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion are subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129651

The Gummy Project Announces Official Launch of E-Commerce Sales Channel

0

  • THE GUMMY PROJECT’S Watermelon Sharks and Peachy Bees are now available for pre-sale purchase at www.shopgummies.com
  • Shipping and fulfilment of online orders will commence on July 11, 2022

Vancouver, British Columbia–(Newsfile Corp. – June 30, 2022) – The Gummy Project (CSE: GUMY) (FSE: 0OS2) (OTCQB: POTVF) (“GUMY” or the “Company”) is pleased to announce the official launch of its new e-commerce site at www.shopgummies.com.

“The launch of our e-commerce site is a major milestone, making our product available across Canada for the first time,” said Anthony Gindin, Chief Marketing Officer at GUMY. “This really marks our official launch into the Canadian market with e-commerce being a major component in our overall sales channel strategy. The site provides a vehicle for continued growth as well as a platform to share our story and fulfil our mandate to support endangered keystone species.”

Both the Watermelon Sharks and Peachy Bees are now available for sale at www.shopgummies.com. Each bag contains 22 gummies with only two grams of sugar while being plant based, gluten free and non-GMO.

Shipping and fulfilment of online orders will commence on July 11, 2022.

“The initial feedback received on both the flavor formulations and the packaging has been tremendous and we are extremely excited that our gummies will now be available to consumers nationwide in Canada through our e-commerce platform,” said Charlie Lamb, President and CEO of GUMY. “Our development team did a wonderful job building a website that not only looks fantastic but is also very user friendly.”

ABOUT THE GUMMY PROJECT

We are a growing community of individuals and organizations who believe small contributions can add up to something big. We sell low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species. We are the only “better for you” candy company that is built to support our planet’s most precious species and ecosystems, while educating our future generations on the steps we must take today, to ensure a viable tomorrow.

Charlie Lamb, President & CEO, Director
Telephone: 1(236) 317-2812 – Toll free (877) 806-2633
E-mail: [email protected]

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates”, “may” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company’s business, financial condition, and results of operations. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129624

Medical Marijuana, Inc. Subsidiary Kannaway Hosts Regional Conference in South Africa

0

SAN DIEGO, CA, June 30, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary Kannaway® will be hosting its South Africa Regional Conference in Cape Town this Saturday, July 2, 2022.

“Kannaway has experienced an incredible start in South Africa and our future in the country is very bright,” said Medical Marijuana, Inc. CEO Blake Schroeder. “South Africa’s CBD market is projected to be a $7 billion market by 2023. We intend to be the driving force around awareness, education, and cannabis-based opportunity to capture a large share of the marketplace.”

This event, which will take place at the Cape Town International Convention Centre, is designed to serve as a premier networking opportunity for entrepreneurs to learn how they can get involved in South Africa’s emerging cannabis industry. It will also feature many seasoned hemp industry professionals including Founder Dr. Stuart Titus, CEO Blake Schroeder, Kannaway South Africa Country Manager, Dudu Mathole, and Kannaway’s first South African International Director, Adriaan Pieterse. The event will provide information about CBD and its benefits, Kannaway’s line of products in South Africa, and entrepreneurial opportunity within the company.

“It has been an amazing experience working with Kannaway and I look forward to speaking with current and potential entrepreneurs at the event about how I’ve found success with the company and how they can too,” said Adriaan Pieterse. “Kannaway is leading the CBD market in South Africa and it is an honor to help drive its mission to improve the wellness of people around the world.”

About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc.and Neuropathix. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visitingwww.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:
Public Relations Contact:
Kathryn Brown
Account Director
CMW Media
P. 858-221-8001
[email protected]
www.cmwmedia.com

Investor Relations Contact:
P. (858) 283-4016
[email protected]

Ketamine Wellness Centers (KWC) Launches Ketamine Wellness Integrative Therapist Directory

0

 

Ketamine Wellness Centers (KWC), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), today officially launched the Ketamine Wellness Integrative Therapist Directory. The comprehensive resource will connect KWC patients with qualified mental health practitioners who can help them process and integrate the benefits of ketamine therapy into their everyday life.

The Ketamine Wellness Integrative Therapist Directory is available to anyone visiting KWC’s website. Cognitive therapists practicing in KWC’s operating states will also have the opportunity to join the network at no cost and more therapists will be added in the future. Patients utilizing KWC’s latest resource can reach out to local mental healthcare providers qualified to help individuals integrate ketamine therapy into their treatment plans. All providers or organizations listed included in the referral network align with KWC’s standards and philosophies of care.

KWC continues to establish itself as a leading mental health treatment provider by offering various methods of accessible care, including ketamine therapy, cognitive therapy and NAD+ infusion therapy. Through its efforts, the company is approaching 100,000 treatments to clinically eligible patients across ArizonaColoradoFloridaIllinoisMinnesotaNevadaTexasUtah and Washington.

“Ketamine therapy is a rapidly growing medical field demonstrating promising results, but many patients overlook the importance of continuous cognitive therapy after their ketamine treatments to maximize the outcomes,” said Kevin Nicholson, CEO of KWC and COO of Delic. “A therapist from the network can work with patients to bridge the outcomes from their completed ketamine therapy into positive, long-term changes in attitudes and behavior. By putting together a comprehensive list of like-minded, qualified mental health professionals and organizations, KWC is continuing to focus on a holistic approach to healing patients suffering from various mental health conditions.”

Thompson Duke Industrial Reaches Production Milestone: Completes 1,000th MCF1 Filling Machine

0

 

Thompson Duke Industrial, the leader in cannabis oil vaporizer device filling and capping equipment, is celebrating a significant milestone: the completion of its 1,000th MCF1 semi-automatic vaporizer filling machine. The MCF1 has the capability to fill as many as 5,000 vaporizer cartridges per day. With 1,000 machines now deployed in the industry, the MCF1 could potentially fill over one billion vaporizer cartridges each year.

Based in Portland, Oregon, Thompson Duke Industrial designs, manufactures and distributes a line of patented, GMP-ready filling and capping machines specifically designed for cannabis vaporizer devices. The MCF1 is Thompson Duke’s semi-automatic filling machine, designed to fill almost any oil vaporizer device available on the market.

“Hitting this milestone shows that there is an increasing need for efficiency and automation in the cannabis industry, and our growth as a company is directly tied to this demand,” said Chris Gardella, Chief Technology Officer for Thompson Duke Industrial. “The ability to quickly adjust dispense volume, fill both high and low viscosity oils, rapidly switch oil formulations, and easily setup and clean the machine are all intentional design decisions behind the MCF1 that allow our clients to operate with extreme accuracy, precision and repeatability.”

This milestone is a significant indicator of the maturation of the cannabis industry. As companies seek competitive advantages, they find the efficiency and accuracy that the MCF1 offers to be extremely valuable. This, along with increased consumer demand, has contributed to the ongoing growth of Thompson Duke and the success of its vaporizer device filling and capping solutions.

The MCF1 is American-made, GMP-ready, patented (United States Patent No. 10,440,989) and cETLus certified in the U.S. and Canada. Features include:

  • Ability to fill every type of cartridge and pod available on the market, as well as capsules, syringes and jars.
  • Adjustable dispense volume, automatic digital temperature control and a patented heated oil dispense system for fine tuning oil viscosity, dispense speed and force.
  • Quick and easy replacement of food-safe, laboratory-grade dispense system components to switch oil formulations in less than one minute. Rapidly clean dispense components with less than one gram of product loss.
  • Lightweight, benchtop, foot pedal-operated design for quick and easy setup, operation and cleaning.

Thompson Duke’s complete line of filling and capping machinery drives success by increasing accuracy, consistency, efficiency and overall throughput for vaporizer device fulfillment operations. To learn more about the MCF1 semi-automatic filling machine, visit: https://thompsondukeindustrial.com/mcf1-semiautomatic-vaporizer-filling-machine.

Great Barrington Dispensary Hosts the Free Summer Lawn Series

0

 

Great Barrington Dispensary announces the beginning of the Summer Lawn Series. This free community event is open to adults 21+ and features free beer, giveaways, and a fun array of games, including lawn Yahtzee, a giant Jenga, volleyball, badminton, a basketball booth, beer pong, yard pong, cornhole, three legged races, and potato sack races.

The Summer Lawn Series will be held on the beautiful rolling hills and large grassy lawns surrounding the dispensary, every Saturday and Sunday, 12 noon to 6pm, beginning July 2.

While the event is free, we ask that you please bring a non-perishable food or cash donation to support the People’s Pantry of Great Barrington.

The Great Barrington Dispensary is the Berkshires friendliest place to get cannabis products and accessories, and is known providing the best customer service in the region. The dispensary also features hand-curated artisanal selections from local family farms, many of which are not available elsewhere in the area.

The Great Barrington Dispensary is located in a historic building, known locally as “The Cannabis Castle.” This impressive building has been lovingly restored and offers a unique, no-pressure environment to browse, ask questions, and find the perfect products for your individual needs and desires.

The Summer Lawn Series will be held at:

The Great Barrington Dispensary
454 Main Street
Great Barrington, MA 01230

Saturdays and Sundays, beginning July 2, 2022.
12 noon – 6pm

While you can purchase cannabis items inside the store, regulations prohibit cannabis consumption on site. You must be 21 years of age or over to be admitted to this fun adult event.

The store is open 7-days a week from 8:00 am to 9:45 pm. To learn more about the Great Barrington Dispensary, visit their website or follow them on Instagram or Facebook.

Number 9 Collection Announces Release of Premium Pre-Ground Flower

0

 

The Number 9 Collection (www.number9collection.com), an all-natural, sustainable, sun-grown cannabis brand in Massachusetts, announced the release of its new, ultra-premium Pre-Ground Flower as part of the Sun Flower Collection.

Pre-Ground Flower is a convenient option for those that appreciate the quality of a whole flower product, but want to roll or pack their own without buying pre-rolled joints or grinding it themselves. Pre-Ground pouches currently feature three popular strains in 5g and 14g resealable pouches:

  • Early Lemon Berry – a cross of Las Vegas Lemon Skunk and Member Berry RBX, is a great choice for artists looking to create – providing notes of sweet lemon, berry, orange, and grapefruit flavors.
  • Jelly Rancher – which has come to be one of the most coveted sativa-dominant strains, and is a great option for beginners and consumers who don’t want an overwhelming high.
  • OG Kush – a hybrid with a unique terpene profile that boasts a complex aroma. It tends to come on strong, and is often enjoyed in the back half of the day to ease stress.
  • Apex – a high-yielding hybrid from Ethos Genetics, which crosses their Mandarin Cookies and Lilac Diesel Bx3. Plants grow large and dense colas, offering an impressive terpene profile that ranges from sweet candied lilac and lemon to grapefruit and fuel. This high-THC strain offers a classic high that will leave you in a fit of laughter.

The No9 Collection features some of the most complex terpene profiles in the state.  The team behind the No9 Collection includes some of the leading growers in the industry, who take great pride in cultivating superior quality, ultra-clean cannabis, with beautiful aromas and unique terpenes.

Today, sophisticated cannabis enthusiasts are paying closer attention to terpene profiles, as a carefully selected blend with optimum ratios will have far better and more predictable effects. That’s why the No9 Collection continues to attract more fans, as its specially curated strains are distinctively enjoyable.

The No9 Collection is based in the agriculture-rich community of Wareham, MA, along Buzzards Bay. The bay’s unique microclimate provides a longer growing season and the perfect setting for the cultivation of high-quality, sun-grown crops. The company is committed to environmentally-friendly farming methods including the use of on-site artesian well water, custom blended amendments, and traditional farming practices. This results in ultra-clean plants with unique characteristics.

If your favorite dispensary doesn’t carry the No9 Collection, ask the store manager to order some and it can usually be delivered within a few days.

If you are a dispensary manager and would like to order the No9 Collection for your store, please contact us at: www.number9collection.com/contact.

Cannabis may only be purchased legally through a licensed dispensary by adults at least 21 years of age.

To learn more about the The No9 Collection, visit the website or follow them on Instagram or Facebook.

Pure Extracts Signs Listing Agreement with Shoppers Drug Mart and Receives Initial Purchase Order

0

VANCOUVER, British Columbia, June 30, 2022 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to announce that its wholly-owned subsidiary, Pure Extracts Manufacturing Corp., has signed a Cannabis Products Supplier Agreement with Medical Cannabis by Shoppers Drug Mart Inc. (“Shoppers”).

The initial purchase order (PO) comprises 6 SKUs including Pure Pulls™ THC and CBD full spectrum oil (FSO) vape cartridges, as well as Pure Chews™ THC and CBD edible gummies. The gummies are sold in Pure Extracts’ proprietary blister packages for ultimate freshness and convenience. These products will be made available on the Medical Cannabis by Shoppers™ platform.

Pure Extracts’ CEO, Ben Nikolaevsky, remarked, “We are excited about joining such a trusted health and wellness retailer as Shoppers and look forward to introducing our brands to their medical customers. This marks another successful milestone in the expansion of our line of branded products and we believe this distribution relationship will contribute a significant amount of revenue to our financials over time.”

About Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)
Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/

Or contact:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
[email protected]

ON BEHALF OF THE BOARD
Ben Nikolaevsky
Ben Nikolaevsky
CEO and Director

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.